Evidence map›Paper›PMID 38427213›Full record

ReviewMolecular neurobiology2024

Protective Effects of Plant-Derived Compounds Against Traumatic Brain Injury.

Danial Khayatan, Seyed Mehrad Razavi, Zahra Najafi Arab, Maryam Khanahmadi, Amirreza Samanian, Saeideh Momtaz, Vasily N Sukhorukov, Tannaz Jamialahmadi, Amir Hossein Abdolghaffari, George E Barreto and 1 more

Open access · hybridAbstract readReview
In one paragraph

Review in Molecular neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Danial KhayatanDepartment of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Seyed Mehrad RazaviDepartment of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Zahra Najafi ArabDepartment of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Maryam KhanahmadiDepartment of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Amirreza SamanianDepartment of Neurology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Saeideh MomtazGI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Vasily N SukhorukovInstitute for Atherosclerosis Research, Osennyaya Street 4-1-207, Moscow, 121609, Russia.
Tannaz JamialahmadiMedical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir Hossein AbdolghaffariDepartment of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. amirhosein172@hotmail.com.
George E BarretoDepartment of Biological Sciences, University of Limerick, Limerick, Ireland. George.Barreto@ul.ie.ORCID http://orcid.org/0000-0002-6644-1971
Amirhossein SahebkarMedical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir.
Islamic Azad University Medical Branch of Tehran · IRMashhad University of Medical Sciences · IRAcademic Center for Education, Culture and Research · IRInstitute for Atherosclerosis Research · RUUniversity of Limerick · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation in the nervous system is one of the key features of many neurodegenerative diseases. It is increasingly being identified as a critical pathophysiological primitive mechanism associated with chronic neurodegenerative diseases following traumatic brain injury (TBI). Phytochemicals have a wide range of clinical properties due to their antioxidant and anti-inflammatory effects. Currently, there are few drugs available for the treatment of neurodegenerative diseases other than symptomatic relief. Numerous studies have shown that plant-derived compounds, in particular polyphenols, protect against various neurodegenerative diseases and are safe for consumption. Polyphenols exert protective effects on TBI via restoration of nuclear factor kappa B (NF-κB), toll-like receptor-4 (TLR4), and Nod-like receptor family proteins (NLRPs) pathways. In addition, these phytochemicals and their derivatives upregulate the phosphatidylinositol-3-Kinase/Protein Kinase B (PI3K/AKT) and nuclear factor erythroid 2-related factor 2 (Nrf2) pathways, which have critical functions in modulating TBI symptoms. There is supporting evidence that medicinal plants and phytochemicals are protective in different TBI models, though future clinical trials are needed to clarify the precise mechanisms and functions of different polyphenolic compounds in TBI.

Indexed as

Brain Injuries, TraumaticNeuroprotective AgentsPhytochemicalsAnimalsHumansPolyphenolsSignal TransductionNeuroprotective AgentsPhytochemicalsPolyphenolsNeurodegenerative diseasesNeuroinflammationOxidative stressPolyphenolTraumatic brain injury (TBI)

Identifiers

PMID38427213
PMCPMC11415436
OpenAlexW4392360083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.